Self-Study Module 3g:

Delirium
Module 3g: Delirium

Abstract ................................................................................................................................. 3
Introduction .......................................................................................................................... 3
Case ..................................................................................................................................... 4
Pathophysiology ................................................................................................................... 5
Assessment .......................................................................................................................... 8
Management ....................................................................................................................... 10
Terminal Delirium ............................................................................................................... 14
Summary ............................................................................................................................. 15
Key Take-Home Points ....................................................................................................... 15
Appendix 1: Folstein Mini-Mental Status Examination .................................................. 17
Appendix 2: Delirium Medication Table ............................................................................ 18
References ......................................................................................................................... 21
Self-Assessment .................................................................................................................. 30
Abstract

Many symptoms and syndromes are commonly encountered in patients with cancer. This module first presents general approaches to symptom management, followed by management of the specific symptoms and syndromes, including: anorexia/cachexia, anxiety, constipation, depression, diarrhea, fatigue, insomnia, menopausal symptoms and sexual health, mucositis, nausea and vomiting, and skin problems.

Any symptom can be debilitating and prevent the patient and family from achieving goals that are important to them. As with other aspects of medicine, tailored management is based on the underlying etiology and pathophysiology. When several symptoms occur together, they can be interrelated and management can be complex.

Introduction

Delirium is both:

- A disturbance of consciousness with reduced awareness of the environment and reduced ability to focus, sustain, or shift attention; and
- A change in cognition manifested by the presence of memory deficits, disorientation, and/or language disturbance, or the development of a perceptual disturbance that is not better accounted for by a pre-existing, established, or evolving dementia.

In contrast to dementia, which develops slowly, delirium develops over a short period of time, usually hours to days, and fluctuates during the course of the day.

There may be associated alterations in sleep patterns (e.g., day-night reversal) and emotional states, nonspecific neurological abnormalities, and a sudden and significant decline in functional ability. (Ref. 1)

While delirium presents with psychiatric symptoms, it is important to remember that these symptoms are manifestations of medical abnormalities and are not due primarily to psychiatric illness.

In a cancer patient, it is particularly important to be vigilant about delirium in the following situations: postoperatively, after chemotherapy treatment, when infections are present, in the presence of tumor necrosis, and in advancing illness. Older patients are particularly susceptible and recover slowly. Mortality rates are high and symptoms can be very distressing for patients and extraordinarily difficult for their families and caregivers.
Delirium can have different clinical presentations or subtypes:

- The **hyperactive** subtype is most often recognized due to its associated behavioral disturbances and the frequent occurrence of psychotic symptoms such as hallucinations or delusional beliefs.
- The **hypoactive** subtype, or quietly delirious patient, is often mistakenly diagnosed with depression or fatigue.
- Not infrequently, patients will present with a **mixed** subtype with symptoms of both hyper- and hypoactive subtypes over the course of a day. Often it is the waxing and waning nature and acute onset that points to the diagnosis of delirium.

Once the diagnosis of delirium is suspected, the underlying cause of the disturbance can be investigated. (Ref. 1) (Ref. 2)

**Prevalence**

Delirium is a common, yet under-recognized and under-treated medical condition. It has been reported in up to 80-85% of terminally ill patients. (Ref. 1) (Ref. 3)

**Prognosis**

An increased risk of delirium is associated with: (Ref. 4) (Ref. 5)

- Postoperative recovery.
- Complications.
- Protracted hospitalization.

Up to 25% of delirious patients die within 6 months, regardless of presenting diagnoses. (Ref. 6)

Delirious elderly patients are at particular risk for complications such as pneumonia, skin ulceration, and falls. (Ref. 7) In the delirious elderly, the risk of dying during a hospital admission increases to between 22 and 76%. (Ref. 8) (Ref. 9)

**Case**

Review the case below, and keep it in mind as you progress through the module. How would you approach the assessment of this patient? What interventions might be appropriate?

A 72-year-old married man with metastatic lung cancer and a 2-day history of confusion and aggressive behavior is admitted to a palliative care unit. Over the next 2 days, he demonstrates intermittent agitation, confusion, and disorientation. These symptoms
seem to be worse at night, while in the midmorning, he is observed to be deeply asleep. At times he shouts out about patients "going missing," and believes that his life is in danger. Unit staff are unable to determine any recognizable pattern in his outbursts. His wife reports that between periods of agitation, he can be cooperative and "back to his normal self." His medications include ranitidine, dexamethasone, gabapentin, and lorazepam. He uses opiate analgesics as needed for pain. Examination reveals nonspecific neurologic abnormalities. His vital signs show mild hypertension, tachycardia, and an elevated respiratory rate. CT scan confirms cerebral metastases. An initial Folstein Mini-Mental State Examination demonstrates problems in orientation, recall, and attention, with a total score of 18 out of 30.

**Pathophysiology**

There are many possible causes of delirium. (Ref. 10) Table 1 presents the most important and potentially life-threatening causes and integrates a mnemonic “I WATCH DEATH.” Causes that are most commonly seen in patients with advanced cancer are bolded and italicized. (Ref. 11) (Ref. 12)

In cancer patients, be particularly vigilant about delirium caused by infection, metabolic imbalances, medications, and tumor necrosis. In addition, infections such as pneumonia or a urinary tract infection can be enough to cause delirium in older patients.
### Table 1: Causes of Delirium

<table>
<thead>
<tr>
<th>Category</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection</td>
<td><em>Encephalitis, meningitis, syphilis, HIV, sepsis</em></td>
</tr>
<tr>
<td>Withdrawal</td>
<td><em>Alcohol, barbiturates, sedative-hypnotics</em></td>
</tr>
<tr>
<td>Acute metabolic</td>
<td><em>Acidosis, alkalosis, electrolyte disturbance, hypercalcemia, hepatic failure, renal failure</em></td>
</tr>
<tr>
<td>Trauma</td>
<td>Closed head injury, heatstroke, postoperative, severe burns</td>
</tr>
<tr>
<td>CNS pathology</td>
<td><em>Abscess, hemorrhage, hydrocephalus, subdural hematoma, infection, seizures, stroke, tumors, metastases, vasculitis</em></td>
</tr>
<tr>
<td>Hypoxia</td>
<td><em>Anemia, CO poisoning, hypotension, pulmonary or cardiac failure</em></td>
</tr>
<tr>
<td>Deficiencies</td>
<td>Vitamin B12, folic acid, niacin, thiamine</td>
</tr>
<tr>
<td>Endocrinopathies</td>
<td>Hyper/hypoaldosteronism, <em>hyper/hypoglycemia</em>, myxedema, hyperparathyroidism, <em>hypercalcemia</em></td>
</tr>
<tr>
<td>Acute vascular</td>
<td>Hypertensive encephalopathy, stroke, <em>arrhythmia, shock, dehydration</em></td>
</tr>
<tr>
<td>Toxins or drugs</td>
<td><em>Medications, chemotherapeutics, illicit drugs</em>, pesticides, solvents</td>
</tr>
<tr>
<td>Heavy metals</td>
<td>Lead, manganese, mercury</td>
</tr>
</tbody>
</table>

Medications, both prescription and over-the-counter, are the most common causes of delirium. Anticholinergic medications are often associated with this problem. Table 2 outlines various medication classes and medications frequently associated with delirium. (Ref. 12) (Ref. 13)
Table 2: Medications Associated With Delirium

<table>
<thead>
<tr>
<th>Category</th>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics</td>
<td>Clonidine</td>
</tr>
<tr>
<td>Anesthetics</td>
<td>Corticosteroids</td>
</tr>
<tr>
<td>Antiasthmatics</td>
<td>Immunosuppressives</td>
</tr>
<tr>
<td>Anticholinergics, including medications with anticholinergic properties</td>
<td>Insulin</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Gastrointestinals</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Muscle relaxants</td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Antimicrobials</td>
<td>Psychotropics, especially those with anticholinergic properties</td>
</tr>
<tr>
<td>Antiparkinsonian</td>
<td>Ranitidine</td>
</tr>
<tr>
<td>Cardiac glycosides</td>
<td>Salicylates</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>Sedatives</td>
</tr>
</tbody>
</table>

Neuropathophysiology

Several cortical and subcortical areas seem to be affected in delirium. Three areas of the prefrontal cortex appear to be involved in certain presentations of delirium. The dorsolateral prefrontal cortex has been associated with executive cognition. Damage to the orbitomedial prefrontal cortex can result in disinhibition. Abnormalities in the function of the anterior cingulate gyrus may account for the lack of language or perseveration sometimes seen in delirious patients. The parietal cortex has also been shown to be affected in delirium. The third major area of the brain affected in delirium is the thalamus and caudate. Its connection with the reticular activating system accounts for the changes in level of consciousness of patients with delirium.
Neurotransmitter changes in the areas noted above have also been implicated in the development of delirium. There are several neurotransmitters involved, including acetylcholine, dopamine, serotonin, GABA, norepinephrine, glutamine, and histamine. Reduced acetylcholine, either through pathologic processes or anticholinergic medications, is a very common cause of delirium.

Higher cognitive and executive functions associated with the cerebrum must remain intact for normal behavior, cognition, and planning.

A recent study demonstrated reduced regional cerebral perfusion during periods of delirium in comparison with studies after recovery. (Ref. 14)

**Assessment**

To assess for delirium, take a careful history, perform a physical examination, carefully observe the patient’s ability to maintain attention over time, and order appropriate investigations (see Table 3). (Ref. 2) (Ref. 11) (Ref. 12) (Ref. 15)

The Folstein Mini-Mental State examination is a screening tool to assess cognitive impairment. Serial administration of the tool can aide in the assessment of delirium and the response to treatment (see Appendix 1). (Ref. 16) Several other tools have been developed to assess delirium, including the Confusion Assessment Method (CAM, a diagnostic tool), (Ref. 17) Delirium Rating Scale (DRS, a diagnostic tool), (Ref. 18) Saskatoon Delirium Checklist (SDC), (Ref. 19) and Memorial Delirium Assessment Scale (MDAS, which is validated as both a screening tool and a severity rating scale). (Ref. 20) These tools are more likely to be used by psychiatrists or palliative medicine physicians who are experts in delirium assessment and management.

While laboratory investigations are not specific or sensitive enough to make a definitive diagnosis of delirium, they can help to determine the underlying cause. An electroencephalogram will usually show generalized slowing, but in the case of delirium due to alcohol withdrawal, it can show low-voltage, fast activity. (Ref. 21) (Ref. 22)
# Table 3: Assessment of Delirium

<table>
<thead>
<tr>
<th>Physical Status</th>
<th>Mental Status</th>
<th>Basic Laboratory</th>
<th>Physical Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td>Interview</td>
<td>Electrolytes</td>
<td>History</td>
</tr>
<tr>
<td>Physical and neurological exam</td>
<td>Cognitive tests</td>
<td>Glucose</td>
<td>Physical and neurological exam</td>
</tr>
<tr>
<td>Review of vital signs</td>
<td>Clock face drawing</td>
<td>Calcium</td>
<td>Review of vital signs</td>
</tr>
<tr>
<td>Review of medical records</td>
<td>Trail A &amp; B</td>
<td>Albumin</td>
<td>Review of medical records</td>
</tr>
<tr>
<td>Review of medications</td>
<td>Folstein Mini-Mental State Examination</td>
<td>Blood urea nitrogen</td>
<td>Review of medications</td>
</tr>
<tr>
<td>History</td>
<td>Interview</td>
<td>Electrolytes</td>
<td>History</td>
</tr>
<tr>
<td>Physical and neurological exam</td>
<td>Cognitive tests</td>
<td>Glucose</td>
<td>Physical and neurological exam</td>
</tr>
<tr>
<td>Review of vital signs</td>
<td>Clock face drawing</td>
<td>Calcium</td>
<td>Review of vital signs</td>
</tr>
<tr>
<td>Review of medical records</td>
<td>Trail A &amp; B</td>
<td>Albumin</td>
<td>Review of medical records</td>
</tr>
<tr>
<td>Review of medications</td>
<td>Folstein Mini-Mental State Examination</td>
<td>Blood urea nitrogen</td>
<td>Review of medications</td>
</tr>
<tr>
<td>History</td>
<td>Interview</td>
<td>Electrolytes</td>
<td>History</td>
</tr>
<tr>
<td>Physical and neurological exam</td>
<td>Cognitive tests</td>
<td>Glucose</td>
<td>Physical and neurological exam</td>
</tr>
<tr>
<td>Review of vital signs</td>
<td>Clock face drawing</td>
<td>Calcium</td>
<td>Review of vital signs</td>
</tr>
<tr>
<td>Review of medical records</td>
<td>Trail A &amp; B</td>
<td>Albumin</td>
<td>Review of medical records</td>
</tr>
<tr>
<td>Review of medications</td>
<td>Folstein Mini-Mental State Examination</td>
<td>Blood urea nitrogen</td>
<td>Review of medications</td>
</tr>
<tr>
<td>History</td>
<td>Interview</td>
<td>Electrolytes</td>
<td>History</td>
</tr>
<tr>
<td>Physical and neurological exam</td>
<td>Cognitive tests</td>
<td>Glucose</td>
<td>Physical and neurological exam</td>
</tr>
<tr>
<td>Review of vital signs</td>
<td>Clock face drawing</td>
<td>Calcium</td>
<td>Review of vital signs</td>
</tr>
<tr>
<td>Review of medical records</td>
<td>Trail A &amp; B</td>
<td>Albumin</td>
<td>Review of medical records</td>
</tr>
<tr>
<td>Review of medications</td>
<td>Folstein Mini-Mental State Examination</td>
<td>Blood urea nitrogen</td>
<td>Review of medications</td>
</tr>
</tbody>
</table>

- Electrolytes
- Glucose
- Calcium
- Albumin
- Blood urea nitrogen
- Creatinine
- SGOT
- Bilirubin
- Alkaline phosphatase
- Magnesium
- Phosphate
- VDRL
- CBC
- Serum drug levels
- Arterial blood gas
- Urinalysis and culture
- Urine drug screen
- Electrocardiogram
- Chest X-ray
- B12, folate
- TSH
Delirium vs. dementia

It is often necessary to differentiate delirium from dementia. (Ref. 15)

Table 4: Differences Between Delirium and Dementia

<table>
<thead>
<tr>
<th></th>
<th>Delirium</th>
<th>Dementia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in alertness</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Disturbance of consciousness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temporal profile of symptoms: Onset</td>
<td>Usually develop quickly, over hours to days</td>
<td>Gradual onset</td>
</tr>
<tr>
<td>Fluctuate over a 24-hour period</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

While memory impairment is common to both, dementia is not associated with a change in alertness or any disturbance in consciousness. The temporal profile is also different. In delirium, symptoms usually develop over hours to days and often fluctuate over a 24-hour period. In dementia, symptoms typically develop much more gradually and there is little or no variation of symptoms over time.

Management

The management of delirium is multifaceted and multidisciplinary. Interventions to treat the underlying causes and ameliorate the troublesome symptoms are of utmost importance. Ensure adequate hydration without creating peripheral or pulmonary edema.

As medications are frequently implicated, decrease or discontinue any unnecessary medications, particularly those with anticholinergic properties. Some analgesics (e.g., meperidine or pentazocine) are strongly anticholinergic, have a high risk of adverse effects (e.g., CNS excitation), and will need to be replaced by other analgesics. Medications may accumulate secondary to prolonged half-life of the drug, or patient-specific attributes such as dehydration, decreased renal clearance, or liver function abnormalities. As opioid clearance is dependent on renal function, reduce the routine opioid dose by at least 50% when urine output is <500 ml/24 hr, and stop routine dosing when urine output is <200 ml/24 hr.
Other reversible causes of delirium that can be quickly diagnosed and treated are hypoglycemia, hypoxia or anoxia, hyperthermia, substance or medication withdrawal, and anticholinergic delirium. For difficult-to-manage delirium, consult a psychiatrist for assistance.

Non-pharmacologic management

A hyperactive delirium can be quite distressing to the observer. Help family understand that what the patient is experiencing might be quite different from what the family is observing.

A number of environmental factors are important when treating delirious patients: (Ref. 23)

- Communicate clearly and concisely with the patient.
- Include frequent reminders of the date and time.
- Always identity important individuals for the patient.
- Minimize the number of different staff working with the patient.
- Provide materials to help reorient the patient (e.g., clock, calendar, and schedule of daily activities).
- Encourage the family and caregivers to bring in familiar objects from home.
- Minimize excess noise and ensure optimal stimulation by nursing staff (e.g., move delirious patients to single rooms, close to the nursing station).
- Control other environmental factors (e.g., temperature and lighting).
- Avoid understimulation; as sensory impairments can make this worse, provide needed glasses and hearing aids.
- Provide sitters to calm and reorient a restless patient; use physical restraints ONLY if there is a high risk of harm to the patient or staff.

Pharmacologic management

Patients with delirium often require antipsychotics and occasionally benzodiazepines. While there is some question about how to treat delirium depending on the goals of care, the type of delirium (hyperactive, hypoactive, or mixed), or whether the etiology is thought to be reversible or irreversible, there may be advantages to treating delirium consistently, regardless of type or etiology. (Ref. 24)
Antipsychotic medications

Antipsychotics are the medications of choice to treat delirium. Depending on the goals of care, those that are nonsedating may be preferred over those that tend to be sedating.

Both haloperidol and chlorpromazine have been shown to be superior to lorazepam for the treatment of delirium. (Ref. 25) Since its development, haloperidol has been the gold standard of pharmacotherapy for treatment of delirium. (Ref. 10) Its use is safe in medically ill patients and it is not sedating. It is available in oral, intramuscular, and intravenous formulations. Common starting doses are:

- **Haloperidol**, 1-2 mg PO, IM, IV q 2-4 h (0.25-0.5 mg q 4 h in the elderly). Titrate to effect. There is a wide dosage range. Doses of 0.5-20 mg IV have been used with success. There are reports of hundreds of milligrams being given over the course of a day with few ill effects; however, administration in the medically ill requires close monitoring for adverse side effects, especially in the elderly.

The need for sedation within the context of agitated behavior is not uncommon. In patients where the use of a concomitant benzodiazepine is undesirable, it may be beneficial to consider a low-potency antipsychotic medication, such as chlorpromazine, to achieve symptomatic control of agitation. Use it cautiously as it is relatively anticholinergic and can contribute to the delirium. (Ref. 26)

- **Chlorpromazine**, 10-25 mg PO, PR, IM, IV q 6 h. Titrate to effect.

In the mid to late 1990s, a new class of antipsychotic medication came into use. These “novel neuroleptics” have a different mechanism of action. Instead of primarily blocking dopamine receptors, as with the older antipsychotics, these new medications act through serotonin receptors in addition to or instead of dopamine receptors. More data are accumulating about the use of the newer atypical antipsychotics, including risperidone, olanzapine, and quetiapine. (Ref. 27) (Ref. 28) These agents may offer an advantage over haloperidol by means of a lower incidence of extrapyramidal side effects. They have been used in the treatment of delirium as shown by previously published case reports and case series. (Ref. 27) (Ref. 29) (Ref. 30) Well-controlled, blinded studies of the atypical antipsychotics in the treatment of delirium have yet to be completed. The FDA has recently determined that the treatment of behavioral disorders in elderly patients with dementia with atypical antipsychotic medications is associated with increased mortality. (Ref. 31) Common starting doses are:

- **Risperidone**(nonsedating), 0.5-1 mg PO q 12-24 h.
- **Olanzapine**(sedating), 2.5-5 mg PO q 12-24 h.
- **Quetiapine**(sedating), 100 mg PO nightly. Titrate to effect. Typical dose is 300-400 mg PO nightly.
Day-night reversal

If there is a sleep cycle disturbance, the use of more sedating antipsychotics (e.g., chlorpromazine, olanzapine, or quetiapine) may be more helpful. Common starting doses are:

- **Chlorpromazine** (sedating), 10 mg PO nightly. Increase by 10 mg PO nightly to 30-50 mg PO nightly.
- **Olanzapine** (sedating), 2.5-5 mg PO nightly. Titrate to effect. Typical dose is 5-10 mg PO daily.
- **Quetiapine** (sedating), 100 mg PO nightly. Titrate to effect. Typical dose is 300-400 mg PO nightly.

Managing adverse effects

Adverse effects of antipsychotics include extrapyramidal effects, tardive dyskinesia, neuroleptic malignant syndrome, akathisia, lowering of the seizure threshold, and QTc prolongation (i.e., >450 msec or >25% of baseline EKGs). All of these side effects may lessen with a decreased dose. Akathisia can be managed with a beta-blocker or benzodiazepine.

Extrapyramidal effects can be managed with anticholinergic medications such as benztropine or diphenhydramine.

Note: Anticholinergic medications and benzodiazepines are generally contraindicated in delirium. Try decreasing the dose of the antipsychotic or try another antipsychotic. This may be the best choice.

For dystonic reactions (e.g., oculogyric crisis, dysphagia, torticollis [cervical muscle spasm producing unnatural twisting of the head], or opisthotonos [tetanic spasm with head and heels bent backward, body bowed forward]):

- **Diphenhydramine**, 25-50 mg PO, IM, IV q 4 h PRN and consult a psychiatrist urgently.

For akathisia (a sense of constant motor restlessness):

- **Benztropine**, 1-2 mg PO daily, bid.

For parkinsonian reactions (tremor, bradykinesia, rigidity, abnormalities of gait and posture):

- **Benztropine**, 1-2 mg IV, IM acutely, then 1-2 mg PO daily, bid.
For tardive dyskinesia (involuntary movements of lips, tongue, jaws, extremities) caused by dopaminergic drugs (e.g., haloperidol) that persists after medication is stopped, consult psychiatry.

**Benzodiazepines**

If the delirium is secondary to specific states (e.g., alcohol withdrawal), a benzodiazepine taper would be the appropriate treatment. Consult a psychiatrist if you are unsure how to appropriately treat alcohol withdrawal.

For all other causes of reversible delirium, avoid benzodiazepines as first-line therapy. They are more likely to cause further disinhibition rather than sedation in this state and in geriatric populations. (Ref. 23)

However, low-dose lorazepam used in conjunction with antipsychotic medication may offer additional benefits when antipsychotic medication alone has not been sufficiently effective, and some studies suggest there may be a synergistic effect that allows for increased effectiveness with decreased adverse effects. (Ref. 32)

Side effects of benzodiazepines include sedation, behavior disinhibition, amnesia, ataxia, respiratory depression, dependence, and delirium. Special attention must be given to the accumulation of benzodiazepines with longer half-lives (such as diazepam and clonazepam).

**Terminal Delirium**

Terminal delirium is delirium that occurs during the dying process. It is always associated with other signs of the dying process (e.g., decreased level of consciousness, changes in breathing patterns, loss of ability to swallow, peripheral cooling, venous pooling/mottling, oliguria, or anuria) (see EPEC™-O Module 6: Last Hours of Living).

Unlike the delirium that occurs earlier in an illness, once a patient is actively dying, end-organ failure, hypoxia, infections, medication toxicity (e.g., opioids), and metabolic disturbances can all contribute to neuronal compromise and delirium that is irreversible. (Ref. 24) (Ref. 33) (Ref. 34)

Manifestations of terminal delirium include restlessness, confusion, tremulousness, hallucinations, mumbling, moaning/groaning, day-night reversal, and a decreasing level of consciousness. If unmanaged, it can evolve to include the presence of myoclonic jerks and seizures. It can be distressing for everyone who watches.

Since the delirium and the dying process are irreversible, the focus of treatment changes from reversing the underlying cause to settling the patient and educating and
calming the family. Most dying patients prefer to be sedated and relaxed, and to have no memory of the event. Benzodiazepines are ideal for this role as they are anxiolytic/hypnotics, muscle relaxants, amnestic, and antiepileptics. Common starting doses are:

- **Lorazepam** 1.0-2.0 mg predissolved in 3-5 ml water, placed against oral or buccal mucosa q 1 h PRN. Once the agitation has settled, calculate the total amount of medication that was used in the last 24 hours, then dose routinely and offer a breakthrough sedative at the bedside.

There is some literature regarding the use of a continuous infusion of intravenous benzodiazepine for sedation for terminal delirium. (Ref. 3) (Ref. 35) In these cases, midazolam has been used as it has a very rapid onset of action and a short half-life.

**Summary**

Delirium is an important clinical entity to recognize, diagnose, and treat in patients receiving end-of-life care. There is still much to learn about predictors of delirium, subtypes of delirium, and symptomatic treatment of this condition. Effective treatment of delirium will decrease the suffering of patients and their families. Restoring a patient's ability to attend to his or her surroundings and environment decreases suffering and facilitates communication with the treatment team and family. This ultimately allows for a better quality of life and death.

**Key Take-Home Points**

1. Delirium is common among the seriously ill.
2. Delirium causes suffering and is associated with increased morbidity and mortality.
3. Treat underlying conditions when possible.
4. Manage with neuroleptics, and with anxiolytics as adjuncts.

**Pearls**

1. Be alert to harbingers of delirium: day-night reversal, altered emotional state, sudden neurological decline.
2. Explain to the family that behaviors associated with delirium do not reflect the patient's personality.
3. Make a partnership with your patient and the family caregiver; draw them into the interdisciplinary team and foster their active participation in the care plan.
4. Additional material can be found in Module 3: Health Professional Resources
   Module 3: Patient Resources.

Pitfall

1. Failing to learn about terminal delirium. Memories of it among surviving family members can be traumatic. Be part of the solution; learn to recognize and manage delirium early.
Use the Folstein Mini-Mental Status tool routinely to assess for cognitive impairment. A total score of >24 is normal; 15-24 indicates mild to moderate impairment; and <15 indicates significant impairment.

<table>
<thead>
<tr>
<th>Maximum Score</th>
<th>Score</th>
<th>Question</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>------</td>
<td>What is the (year) (day) (month) (date) (season)?</td>
</tr>
<tr>
<td>5</td>
<td>------</td>
<td>Where are we (province) (country) (town) (hospital) (floor)?</td>
</tr>
<tr>
<td>3</td>
<td>------</td>
<td>Name 3 objects: glass, blanket, pencil</td>
</tr>
<tr>
<td>5</td>
<td>------</td>
<td>Serial 7’s or alternately spell “world” backwards</td>
</tr>
<tr>
<td>3</td>
<td>------</td>
<td>Ask for the 3 objects repeated above</td>
</tr>
<tr>
<td>2</td>
<td>------</td>
<td>Name a pencil and watch</td>
</tr>
<tr>
<td>1</td>
<td>------</td>
<td>Repeat the following – “no ifs, ands, or buts”</td>
</tr>
<tr>
<td>3</td>
<td>------</td>
<td>Follow a 3-stage command: “take a paper in your right hand, fold it in half, and give it to me”</td>
</tr>
<tr>
<td>1</td>
<td>------</td>
<td>Read and obey the following: Close Your Eyes</td>
</tr>
<tr>
<td>1</td>
<td>------</td>
<td>Write a sentence</td>
</tr>
<tr>
<td>1</td>
<td>------</td>
<td>Copy a design</td>
</tr>
<tr>
<td>30</td>
<td>------</td>
<td>TOTAL SCORE</td>
</tr>
</tbody>
</table>
## Appendix 2: Delirium Medication Table

### Delirium Medication Table

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name(s)</th>
<th>Dosage Forms/ Time C_{max}</th>
<th>Elimination t\textsubscript{1/2}</th>
<th>Route of Elimination</th>
<th>Adult Doses</th>
<th>Pediatric Doses</th>
<th>Adverse Effects</th>
<th>Common Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorpromazine</td>
<td>Various; Thorazine® is an example: tabs: 10, 25, 50, 100, 200 mg liquid: 100 mg/ml inj: 25 mg/ml supp: compounded</td>
<td>PO: 2.8 hr IM: 1-4 hr IV: 2-4 hr</td>
<td>6 hr</td>
<td>Liver metabolism: extensive PO: undergoes extensive first-pass metabolism Renal excretion: 23%</td>
<td>PO, PR, IM, IV q 6-12 h nausea, hiccups: 25-50 mg PO PR, IM, q 8-12 h PRN</td>
<td>antipsychotic dose: ☺ antiemetic: 2 mg/kg/24h PO, IV + q 4-6 h</td>
<td>• anticholinergic AE • EPS • Sedation (haloperidol not as sedating) • hypotension • itching</td>
<td>• CNS depressants • anticonvulsants • barbiturates • lithium</td>
</tr>
<tr>
<td>Diphenhydramine</td>
<td>Various; Benadryl® is an example: caplets: 25, 50 mg elixir: 12.5 mg/5 ml children’s liquid: 6.25 mg/5 ml inj: 50 mg/ml cream: 1, 2%</td>
<td>PO: 2-4 hr Metabolites: 8.6-10 hr</td>
<td>4-8 hr</td>
<td>Liver metabolism: 50% large first-pass effect</td>
<td>25–50 mg PO, IV tid, qid, or 10-50 mg IM, IV q 4 h PRN or routinely (max 400 mg/24h )</td>
<td>5 mg/kg/24h PO IM, IV + q 4-6 h PRN or routinely</td>
<td>• sedation • dizziness • confusion • nausea/vomiting • hypersensitivity • arrhythmias</td>
<td>• CNS depressants • ephedrine • MAOIs</td>
</tr>
<tr>
<td>Generic Name</td>
<td>Trade Name(s)</td>
<td>Dosage Forms/ Time C_{max}</td>
<td>Elimination t_{1/2}</td>
<td>Route of Elimination</td>
<td>Adult Doses</td>
<td>Pediatric Doses</td>
<td>Adverse Effects</td>
<td>Common Interactions</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------</td>
<td>----------------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>----------------</td>
<td>----------------</td>
<td>-------------------</td>
</tr>
<tr>
<td><strong>Haloperidol</strong>&lt;br&gt;Dopaminergic antiemetic, non-sedating neuroleptic</td>
<td>Various; Haldol&lt;sup&gt;®&lt;/sup&gt; is an example: tabs: 0.5, 1, 2, 5, 10, 20 mg liquid: 2 mg/ml inj: 5 mg/ml</td>
<td>PO: 2-6 hr IM: 20 minutes</td>
<td>21 hr (range: 10-38 hr)</td>
<td>Liver metabolism: Renal excretion: 33-40% Feces: 15%</td>
<td>0.5-5 mg PO SC, IM q 4-6 h PRN or routinely</td>
<td>☑</td>
<td>☑</td>
<td>diarrhea&lt;br&gt;sedation&lt;br&gt;hypotension&lt;br&gt;hypersensitivity&lt;br&gt;alcohol&lt;br&gt;anticholinergics&lt;br&gt;barbiturates, β-blockers&lt;br&gt;cimetidine, clonidine&lt;br&gt;disulfiram&lt;br&gt;l-dopa, lithium&lt;br&gt;metoclopramide&lt;br&gt;mercaptophenylamine&lt;br&gt;phentolamine&lt;br&gt;propranolol&lt;br&gt;quetiapine, valproate&lt;br&gt;vitamin C</td>
</tr>
<tr>
<td><strong>Olanzapine</strong>&lt;br&gt;Atypical neuroleptic</td>
<td>Various; Zyprexa&lt;sup&gt;®&lt;/sup&gt; is an example: tabs: 2.5, 5, 7.5, 10, 15, 20 mg ODT: 5, 10, 15, 20 mg inj: 10 mg/vial</td>
<td>PO: 6 hr IM: 15-45 minutes</td>
<td>21-54 hr (mean 30 hr)</td>
<td>Liver metabolism: extensive Renal excretion: 57% Feces: 30%</td>
<td>2.5 mg PO daily and advance to 5-10 mg/24h</td>
<td>☑ ☑</td>
<td>☑</td>
<td>dizziness&lt;br&gt;hypotension&lt;br&gt;hyperkinesia&lt;br&gt;sedation&lt;br&gt;somnolence&lt;br&gt;nausea&lt;br&gt;levodopa&lt;br&gt;carbamazepine</td>
</tr>
<tr>
<td><strong>Perphenazine</strong>&lt;br&gt;Neuroleptic</td>
<td>Various; Trilafon&lt;sup&gt;®&lt;/sup&gt; is an example: tabs: 2, 4, 8, 16 mg concentrate: 16 mg/5 ml</td>
<td>PO: 4-8 hr</td>
<td>9.5 hr (range, 8.4-12.3 hr)</td>
<td>Liver Metabolism: extensive</td>
<td>8-16 mg PO bid-qid (max 64 mg/24h, 24 mg/24h in ambulatory patients)</td>
<td>☑</td>
<td>☑</td>
<td>anticholinergic AE&lt;br&gt;EPS&lt;br&gt;Sedation (haloperidol not as sedating)&lt;br&gt;hypotension&lt;br&gt;itching&lt;br&gt;CNS depressants&lt;br&gt;anticonvulsants&lt;br&gt;barbiturates&lt;br&gt;lithium</td>
</tr>
<tr>
<td><strong>Quetiapine</strong>&lt;br&gt;Atypical neuroleptic</td>
<td>Various; Seroquel&lt;sup&gt;®&lt;/sup&gt; is an example: tabs: 25, 100, 200, 300 mg</td>
<td>PO: 1.5 hr</td>
<td>6 hr</td>
<td>Liver metabolism: extensive first pass Renal excretion: 70%-73% Feces: 20-21%</td>
<td>25 mg PO bid and titrate</td>
<td>☑ ☑</td>
<td>☑</td>
<td>dizziness&lt;br&gt;hypotension&lt;br&gt;hyperkinesia&lt;br&gt;sedation&lt;br&gt;somnolence&lt;br&gt;nausea&lt;br&gt;levodopa&lt;br&gt;carbamazepine</td>
</tr>
</tbody>
</table>
## Delirium (antipsychotics and EPS antidotes)

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name(s)</th>
<th>Dosage Forms/ Time C&lt;sub&gt;max&lt;/sub&gt;</th>
<th>Elimination t&lt;sub&gt;1/2&lt;/sub&gt;</th>
<th>Route of Elimination</th>
<th>Adult Doses</th>
<th>Pediatric Doses</th>
<th>Adverse Effects</th>
<th>Common Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risperidone</td>
<td>Various; Risperdal&lt;sup&gt;®&lt;/sup&gt; is an example: tabs: 0.25, 0.5, 1, 2, 3, 4 mg ODT: 0.5, 1, 2 mg syrup: 1 mg/ml</td>
<td>PO tabs: 1-2 hr PO solution: 1 hr</td>
<td>PO: 20-30 hr Metabolites: 21-30 hr</td>
<td>Liver metabolism: extensive</td>
<td>0.5 mg PO bid and titrate weekly</td>
<td>☺☺</td>
<td>• EPS • dizziness • hypotension • hyperkinesia • somnolence • nausea</td>
<td>• levodopa • carbamazepine</td>
</tr>
</tbody>
</table>
Delirium can occur at any age, but elderly persons are especially prone to develop it. In later life, it is often a conspicuous feature of systemic or cerebral disease and drug (notably anticholinergic) toxicity, and may constitute a grave prognostic sign. Its development in a hospitalized patient may interfere with his or her management, disrupt ward routine, and cause medicolegal complications as a result of patient injury. Acute onset of a fluctuating level of awareness, accompanied by sleep-wake cycle disruption, lethargy or agitation, and nocturnal worsening of symptoms, are diagnostic. Early recognition of delirium and treatment of its underlying cause are essential.

Deliirium is highly prevalent in terminally ill patients, especially in the last weeks of life, when some cognitive impairment develops in as many as 85% of patients. Delirium is associated with increased morbidity in terminally ill patients and can interfere with pain and symptom control. The cause of delirium is usually multifactorial and often cannot be found or reversed in dying patients. Non-pharmacologic and pharmacologic interventions are effective in controlling the symptoms of delirium in terminally ill patients. Haloperidol and other newer neuroleptics are safe and effective in eliminating delirium for some patients. In approximately one-third of patients, delirium can be managed successfully only by providing sedation.

This article addresses the effect of delirium, as a comorbid diagnosis in hospitalized patients, on patient length of stay. Length of stay for delirious patients was found to be significantly longer (2.2-fold; 95% confidence interval 1.5-3.3) than for matched controls. Delirium, as a comorbid diagnosis in general hospital patients, is associated with an increased use of resources. Early diagnosis may limit this effect, as well as morbidity.


The authors identified the added cost attributable to postoperative delirium in patients undergoing elective surgery. Patients (n=500) were evaluated before elective surgery, assessing cognitive functioning, medical conditions, medication usage, and other information regarding their health status. Using DSM-IV criteria, patients were assessed for delirium on postoperative days 1-4. Of the 500 patients assessed, 57 (11.4%) developed delirium during the study.


One hundred thirty-three cases of organic mental disorders were analyzed from a total of 771 patients who were referred for psychiatric consultation from a general hospital. Delirium and dementia were the most commonly diagnosed conditions, and features of these disorders, particularly in the geriatric population, are described. Delirium occurred more frequently in patients with multiple medical problems, was the indicator of poor prognosis having the highest mortality rate, and was usually undiagnosed by the referring physician.

The article describes an examination of the relative frequency and outcome of clinical subtypes of delirium in 94 older hospital patients with delirium from a prospective study of 225 admissions. Also examined were illness severity on admission, prior cognitive impairment, mortality, duration of hospital stay, and hospital-acquired complications. Of the 94 patients, 20 (21%) had a hyperactive delirium, 27 (29%) had a hypoactive delirium, 40 (43%) had a mixed hypoactive-hyperactive psychomotor pattern, and 7 (7%) had no psychomotor disturbance. There were significant differences between the four groups in illness severity (P<0.05), length of hospital stay (P<0.005), and frequency of falls (P<0.05). Patients with hypoactive delirium were sicker on admission, had the longest hospital stay, and were most likely to develop pressure sores. Patients with hyperactive delirium were most likely to fall in hospital.


Medically ill patients diagnosed at index admission as delirious (i.e., suffering cognitive decline and an altered state of consciousness) had higher fatality rates than demented, cognitively intact, or depressed patients. At 1-year follow-up, the death rate of those who had been delirious was still higher than that of demented patients. Delirious patients were more likely to have a diffusely slow EEG, tachycardia, and hyperthermia, and lower mean systolic and diastolic blood pressure.


This article discusses research in the areas of morbidity and mortality, epidemiologic risk factors, phenomenology, pathophysiology, and treatment of delirium. Delirium assessment instruments are reviewed. The neuropathophysiologic understanding of delirium is discussed in the context of important CNS neural circuitry. Pharmacologic treatments of delirium in adults and children are outlined.


A possible mechanism of delirium was examined using xenon-enhanced computed tomography to measure the regional cerebral blood flow (rCBF) of patients both during delirium and after improvement from delirium. Findings that reduced rCBF during delirium becomes normal once delirium improves suggest that a possible cause of delirium may be the cerebral hypoperfusion.


A new standardized confusion assessment method (CAM) that enables nonpsychiatric clinicians to detect delirium quickly in high-risk settings was developed and validated. The study included 56 subjects, ranging in age from 65 to 98 years. The CAM instrument, which can be completed in less than 5 minutes, consists of nine operationalized criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). An a priori hypothesis was established for the diagnostic value of four criteria: acute onset and fluctuating course, inattention, disorganized thinking, and altered level of consciousness. The CAM algorithm for diagnosis of delirium requires the presence of both the first and the second criteria and of either the third or the fourth criterion. The CAM algorithm has the highest predictive accuracy for all possible combinations of the nine features of delirium, and is sensitive, specific, reliable, and easy to use for identification of delirium.

A 10-item clinician-rated symptom-rating scale for delirium is presented. As compared to demented, schizophrenic, and normal control groups, 20 delirious subjects scored significantly higher on the scale, which quantitates multiple parameters affected by delirium. The scale can be used alone or in conjunction with an electroencephalogram and bedside cognitive tests to assess the delirious subject.


Low-dose scopolamine, given as presurgical medication, resulted in low levels of serum anticholinergic activity and caused measurable cognitive impairment in 18 psychiatrically healthy elderly patients. The degree of impairment was directly related to serum anticholinergic activity levels and, in the small subgroup of patients scheduled for spinal anesthesia, to CSF anticholinergic activity. Two of the mental status tests used, the Rey Auditory-Verbal Learning Test and the Saskatoon Delirium Checklist, were sensitive enough to detect these mild drug-induced changes, while two other tests, the Mini-Mental State and the Symbol Digit Modalities Test, were not.
Two studies were conducted in medically hospitalized cancer and acquired immunodeficiency syndrome (AIDS) patients to assess the reliability and validity of a new measure of delirium severity, the Memorial Delirium Assessment Scale (MDAS). Results indicated high levels of inter-rater reliability for the MDAS and the individual MDAS items, as well as high levels of internal consistency. Mean MDAS ratings differed significantly between delirious patients and the comparison sample of patients with other cognitive impairment disorders or no cognitive impairment. The second study compared MDAS ratings of 51 medically hospitalized delirious patients with cancer and AIDS made by one clinician to ratings on several other measures of delirium (Delirium Rating Scale, clinician's ratings of delirium severity) and cognitive functioning (Mini-Mental State Examination) made by a second clinician. Results demonstrated a high correlation between MDAS scores and ratings on the Delirium Rating Scale, the Mini-Mental State Examination, and clinician's global ratings of delirium severity. The findings indicate that the MDAS is a brief, reliable tool for assessing delirium severity among medically ill populations that can be reliably scored by multiple raters. The MDAS is highly correlated with existing measures of delirium and cognitive impairment, yet offers several advantages over these instruments for repeated assessments, which are often necessary in clinical research.


The efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients were examined with a randomized, double-blind, comparison trial. Two hundred forty-four nondelirious, medically hospitalized AIDS patients were monitored prospectively for the development of delirium. Patients entered the treatment phase of the study if they met DSM-III-R criteria for delirium and scored 13 or greater on the Delirium Rating Scale. Efficacy and side effects associated with the treatment were measured with repeated assessments using the Delirium Rating Scale, the Mini-Mental State, and the Extrapyramidal Symptom Rating Scale. Treatment with either haloperidol or chlorpromazine in relatively low doses resulted in significant improvement in the symptoms of delirium as measured by the Delirium Rating Scale. No improvement in the symptoms of delirium was found in the lorazepam group. Cognitive function, as measured by the Mini-Mental State, improved significantly from baseline to day 2 for patients receiving chlorpromazine. Treatment with haloperidol or chlorpromazine was associated with an extremely low prevalence of extrapyramidal side effects. All patients receiving lorazepam, however, developed treatment-limiting adverse effects. Although only a small number of patients had been treated with lorazepam, the authors became sufficiently concerned with the adverse effects to terminate that arm of the protocol early.


In 106 clinically stable patients with schizophrenia, the anticholinergic load was associated with lower scores on measures of attention and declarative memory, including several measures of auditory and visual memory and two tests of complex attention, but was unrelated to intelligence, simple attention, working memory, executive functions, conceptual fluency, or motor speed.

Delirium is generally characterized by acute disturbances of consciousness, cognition, and perception that are precipitated by an underlying medical condition. The gold standard of psychiatric treatment is to treat the underlying medical cause and use high-potency antipsychotics to treat the clinical manifestations of delirium. In the early 1990s, a new generation of novel antipsychotics was developed. Their mechanism of action, preferential serotonergic (5HT(2a)) blockade, results in a markedly lower rate of extrapyramidal side effects, an advantage over the typical, older antipsychotic medications. These agents have been shown to be effective and well tolerated in common psychotic disorders (e.g., schizophrenia or bipolar disorder). This paper reviews the pertinent literature and summarizes tentative guidelines for novel antipsychotic use in delirium.


Delirium is a common psychiatric illness among medically compromised patients. There is an increasing opportunity to use atypical antipsychotics to treat delirium. A prospective open trial on risperidone was carried out in 10 patients with delirium. At a low dose of 1.7 mg/d, on average, risperidone was effective in 80% of patients, and the effect appeared within a few days. There were no serious adverse effects. However, sleepiness (30%) and mild drug-induced parkinsonism (10%) were observed; the symptom of sleepiness was cause for not increasing the dose. This trial is a preliminary open study with a small sample size, and further controlled studies will be necessary.


Delirium is common among cancer patients, especially those with advanced disease. Typical treatment involves addressing the underlying cause, if possible; eliminating nonessential and/or other drugs that can worsen confusion; manipulating the environment; administering antipsychotic drugs to control symptoms and agitated behavior; and attempting to clear the patient’s sensorium. The newer atypical antipsychotics may have potential in the treatment of delirium and have the added benefit of causing less akathisia and other extrapyramidal side effects. The potential utility of this atypical antipsychotic in the palliative care setting is discussed.


The last hours of living can be one of the most important times in the life of any patient and his or her family. With appropriate preparation and careful management of the process by skilled clinicians, dying and death can be a comfortable and even rewarding experience for everyone involved. After death, careful attention to the grief of survivors can help them cope with their loss and rebuild their lives.


Delirium is often a distressing symptom for both patients and their families, and its prevention is important. New strategies to prevent agitated delirium that are practically available should be explored.


In 39 of 100 cancer patients admitted to the palliative care unit at Edmonton General Hospital, the presence of delirium during the last week of life required psychotropic drug treatment. In 10 of the 39 delirious patients, symptoms were controllable only by sedation; this was achieved in 9 patients by a continuous subcutaneous infusion of midazolam. Although haloperidol is considered to be the treatment of choice in agitated, delirious cancer patients, these data may suggest other palliative care treatment strategies for these patients.
Self-Assessment

Module 3g: Delirium

3. Mrs. Mugia has malignant melanoma, metastatic to inguinal lymph nodes that were resected 2 years ago. There is no evidence of recurrence. She also has moderate Alzheimer’s-type dementia, and chronic obstructive pulmonary disease. She has chronic pain in her back, hips, and knees that is moderately well controlled with ibuprofen. She is hospitalized for an exacerbation of her chronic obstructive pulmonary disease. Her overall level of consciousness has declined. On the third hospital day she begins moaning and crying out. Oncology is consulted to rule out brain metastases. Delirium is:

☐ a). unlikely
☐ b). rarely related to medications
☐ c). sometimes misinterpreted as pain
☐ d). usually inevitable

4. Mrs. Mugia’s agitation worsens, and the goal is to reverse the symptoms of delirium. She is initially best managed with:

☐ a). midazolam
☐ b). haloperidol
☐ c). diazepam
☐ d). amitriptyline
Self-Assessment Answers

Question 3. The correct answer is: c)

This question is aimed at diagnosing delirium. Delirium is very common in those hospitalized with advanced disease. Moaning and crying out, particularly in the setting of diminished level of consciousness, is a frequent sign of delirium. Particularly in the patient with a history of pain, it may be misinterpreted. Although common, delirium is not inevitable, and its treatment should be pursued. She may also need analgesics.

Question 4. The correct answer is: b)

This question is aimed at understanding the treatment of delirium. Haloperidol, a relatively nonsedating neuroleptic, is the most appropriate when the goal is reversing the delirium. It can be given PO, IV, or SC; IM is possible but not necessary. The benzodiazepines midazolam and diazepam may sedate her, but won’t reverse the delirium. Their use would be appropriate if the goal were to settle symptoms, but not reverse the delirium. Amitriptyline is an antidepressant.